增强随机对照试验可信度检查:通往更可靠证据的路径
该文总结用于防止不可信随机对照试验(RCT)进入荟萃分析的工具,提出六个检查点:发表前检查、发表后检查、聚合数据荟萃分析期间检查、个体参与者数据(IPD)检查、伞状综述检查及指南检查。共检索到七种工具,均评估试验伦理、注册、随访合理性及基线数据,但均未经正式验证。系统综述作者应在数据提取前评估RCT可信度,并将不可信试验排除。
要点
- 系统综述作者应使用可信度工具筛查RCT,排除有未解决问题试验。
- 七种工具均评估伦理、注册、随访合理性及基线数据,但无一正式验证。
- 推荐在系统综述中整合可信度评估,并纳入PRISMA报告。
核心结论
- 六个层级的可信度检查可防止不可信RCT影响临床实践。
- 系统综述层面应将可信度评估整合入PRISMA。
研究设计与样本
- 检索PubMed中评估RCT可信度的工具,总结并提六个检查点。
主要发现
- 发表前和发表后检查共发现七种工具及一套国际共识声明。
- 四种工具经试点,一种以预印本发表(INSPECT-SR),三种经非德尔菲共识达成。
- 无工具经正式验证,仅IPD-Integrity进行了初步验证。
- 所有工具均评估试验伦理、注册、随访合理性及基线数据;六种评估作者组大小与试验背景、招募时间线及结局数据的合理性。
- 三种工具推荐用于研究使用者和编辑检查;全部七种工具推荐用于系统综述作者。
关键数值与推荐
- 系统综述作者筛查发现重大问题可在数据提取前排除试验。
- 有未解决问题研究应排除,数量及原因应出现在流程图。
- IPD层面检查应检测意外值和数据模式,IPD-Integrity和INSPECT-SR扩展可做到。
- 伞状综述应检查原始综述是否评估可信度,必要时进行原始RCT评估或仅纳入已检查的SR。
- 指南应评估纳入研究的可信度。
临床怎么用
- 系统综述作者应在研究选择后、数据提取前使用工具筛查RCT可信度。
- 对筛查发现重大问题的试验予以排除,并在流程图中报告数量及原因。
- 期刊应加强数据共享政策,自动提醒评论,标记撤稿参考文献并透明沟通调查结果。
局限性
- 所有工具均未经正式验证,仅IPD-Integrity进行了初步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Systematic reviews (SRs) of randomized controlled trials (RCTs) are crucial for shaping clinical practice, but are only as good as the RCTs on which they are based. We aimed to summarize tools to prevent untrustworthy RCTs from entering meta-analysis. We propose six checkpoints: prepublication checks, postpublication checks, checks during aggregate-data meta-analysis, checks of individual participant data (IPD), and checks for umbrella reviews and guidelines. STUDY DESIGN AND SETTING: We searched PubMed for tools assessing RCTs for trustworthiness. RESULTS: Before publication, trialists must guarantee trustworthiness by providing registration details, protocol, datasets, and code. Journals should enhance data-sharing policies for RCTs. Research users should evaluate trials postpublication and report concerns to journals or platforms like PubPeer. Journals should be automatically alerted to comments, mark retracted references, expedite investigations, and communicate findings transparently. We found seven tools for both prepublication and postpublication checks and an international consensus set of statements for postpublication checks. Four were piloted, while one has been published as preprint (INveStigating ProblEmatic Clinical Trials in SR [INSPECT-SR]). Three were achieved by non-Delphi consensus, while INSPECT-SR used a Delphi process. No tools were formally validated; one (IPD-Integrity) underwent preliminary validation. All address trial ethics, registration, follow-up plausibility, and baseline data; 6 of 7 tools assess the plausibility of the authors' group size relative to trial context, recruitment timelines, and outcome data. Three were recommended for research user and editor checks. Systematic reviewers should assess RCTs for trustworthiness. All seven tools were recommended for systematic reviewers. Positive systematic reviewer screening for major issues can eliminate trials after study selection but before data extraction. Studies with unresolved issues should be excluded; their count should appear in the flow diagram with reasons. All tools assess study-level data. IPD-level checks should detect unexpected values and data patterns; IPD-Integrity and a developing INSPECT-SR extension can do so. Umbrella reviews should check whether original reviews assessed trustworthiness and, if needed, perform primary RCT assessments or only include SRs that have conducted checks. Guidelines should evaluate the trustworthiness of included studies. CONCLUSION: Six levels of trustworthiness checks can prevent untrustworthy RCTs from influencing practice. At the SR level, trustworthiness assessments should be integrated in Preferred Reporting Items for Systematic Reviews and Meta-analyses.
引用
- Papapanou M, Siristatidis C, Paraskevas T, et al. Enhancing trustworthiness checks of randomized controlled trials: a pathway to more reliable evidence. J Clin Epidemiol. 2026. PMID: 41912012. doi:10.1016/j.jclinepi.2026.112259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。